Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ELAPR002f Injectable · 1 trial · 1 indication
The ACSS is a 5-point photonumeric scale that assesses the appearance of cheek smoothness vs coarseness where 0=none and 4=extreme. A responder is a participant with at least 1-grade improvement from baseline in ACSS.
The AFLS is a 5-point photonumeric scale that assesses the appearance of fine lines where 0=none and 4=diffuse superficial lines. A responder is a participant with at least 1-grade improvement from baseline in AFLS.
| Arm | Type | Description |
|---|---|---|
| ELAPR002f Injectable Gel | EXPERIMENTAL | Participants will receive 3 treatment sessions 1 month apart of ELAPR002f injectable gel and will be followed for 4 months. |
| Name | Type | Description |
|---|---|---|
| ELAPR002f Injectable Gel | DEVICE | Intradermal Injections |
Inclusion Criteria: * Participants in general good health, in the opinion of the investigator, with no known active COVID-19 infection, seeking improvement of facial skin quality. * Moderate or severe (symmetric grade 2 or 3 on the Allergan Fine Lines Scale \[AFLS\] and Allergan Cheek Smoothness Sc...
ELAPR002f Injectable is an investigational injectable gel being studied for the treatment of atrophic acne scars and for the improvement of skin quality deficit in adults. It is in clinical development for dermatology indications, including acne scars and skin quality issues.
ELAPR002f Injectable is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting clinical trials to evaluate the safety and effectiveness of this injectable gel for dermatology applications.
ELAPR002f Injectable is in Phase 2 and Phase 3 clinical trials. One Phase 2 study has been completed, and two Phase 3 studies are listed, one completed and one currently recruiting participants. It remains investigational and has not been approved by regulatory authorities.
ELAPR002f Injectable has been studied in three clinical trials. NCT05995340 is a completed Phase 3 study in atrophic acne scars with 157 participants in Canada and Germany. NCT06151535 is a completed Phase 2 study in skin quality deficit with 30 participants in Italy. NCT07207369 is a recruiting Phase 3 study in acne scars with 395 participants in the United States.
ELAPR002f Injectable is the name used in clinical trials for this product. The drug is consistently referred to as ELAPR002f Injectable in the study records, and no alternative names have been identified in the available information.